Countagen is a Stockholm-based biotechnology company committed to accelerating the pace of gene editing advancements by providing high-resolution gene editing characterization. Out technology platform, LockSeq, is a novel targeted NGS library preparation based on a unique gap-fill chemistry that minimizes target dropouts and amplification bias, enabling routine and standardized gene editing characterization at every stage of development. The LockSeq Advantage: - Simultaneous Indel Profiling: Profile and validate hundreds of genomic loci in a single reaction. - High Sensitivity: Robust detection of on- and off-target edits down to 0.1% frequency. - Broad Compatibility: Compatibility across sequencing platforms. - Cost-Efficient Scalability: Scale panels and samples with minimal target dropout and uniform target capture. 📍 Based in the SciLifeLab / Karolinska Institutet ecosystem, Solna.
| Website | https://countagen.com/ |
| Employees | 6 (4 on RocketReach) |
| Founded | 2020 |
| Phone | +1 925-603-8000 |
| Industry | Biotechnology Research |
| Keywords | Gene Editing, Genetic Engineering, Genotyping, Genome Sequencing, Biotechnology, Therapeutics, Genetic Testing, Life Sciences, Precision Medicine, Drug Development, Biomarker Discovery, Personalized Medicine, Molecular Diagnostics, Clinical Diagnostics, Research Tools, Diagnostic Tools, Pharmaceutical Research |
| Competitors | Thermo Fisher Scientific, Natera, Guardant Health, Myriad Genetics, Foundation Medicine, Veracyte, Inc., Invitae, Lengo Therapeutics, PathAI, Genomic Health +41 more (view full list) |
Looking for a particular Countagen employee's phone or email?
Felix Neumann is the CEO and Co-founder of Countagen.
4 people are employed at Countagen.